Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer
Autore:
Haslinghuis, LM; Krenning, EP; de Herder, WW; Reijs, AEM; Kwekkeboom, DJ;
Indirizzi:
Univ Rotterdam Hosp, Dept Nucl Med, NL-3015 GD Rotterdam, Netherlands UnivRotterdam Hosp Rotterdam Netherlands NL-3015 GD terdam, Netherlands Univ Rotterdam Hosp, Dept Internal Med, NL-3015 GD Rotterdam, Netherlands Univ Rotterdam Hosp Rotterdam Netherlands NL-3015 GD terdam, Netherlands
Titolo Testata:
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
fascicolo: 6, volume: 24, anno: 2001,
pagine: 415 - 422
SICI:
0391-4097(200106)24:6<415:SRSITF>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
RADIONUCLIDE THERAPY; HOSPITAL EXPERIENCE; CARCINOMA; RECURRENT; TUMORS; ANALOG;
Keywords:
thyroid carcinoma; somatostatin; receptor imaging;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
21
Recensione:
Indirizzi per estratti:
Indirizzo: Kwekkeboom, DJ Univ Rotterdam Hosp, Dept Nucl Med, 40 Dr Molewaterplein, NL-3015 GD Rotterdam, Netherlands Univ Rotterdam Hosp 40 Dr Molewaterplein Rotterdam Netherlands NL-3015 GD
Citazione:
L.M. Haslinghuis et al., "Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer", J ENDOC INV, 24(6), 2001, pp. 415-422

Abstract

The aim of this study was to compare the results of somatostatin receptor scintigraphy (SRS) and of radioiodine scintigraphy in patients with metastatic differentiated thyroid carcinoma during L-thyroxine suppression therapyand after withdrawal. Twenty-five patients were studied: 16 patients had papillary cancer and 12 of them had metastatic disease; 9 patients had follicular cancer and 7 of these had known metastases. In 7 patients SRS was performed during thyroxine withdrawal, in 12 during thyroxine therapy within 9months from radioiodine scintigraphy, in 6 others both during suppression therapy and after withdrawal. SRS was positive in 18 of 25 (72%) patients. It demonstrated lesions in 11 of 13 (85%) patients after thyroxine withdrawal and in 12 of 18 (67%) patients during thyroxine suppression. In 6 patients in whom a direct comparison was made before and after withdrawal, essentially the same information was obtained. Six of 8 (75%) patients with lesions that did not concentrate radioiodine showed uptake of labeled octreotidein these lesions. In 5 of 17 (29%) patients whose tumors concentrated radioiodine, no uptake was found during SRS. Conclusions: 1) in patients with metastatic differentiated thyroid carcinoma, tumor sites can be visualized using SRS; 2) there is no need to withdraw patients from suppression therapyin order to perform SRS; 3) in some patients whose lesions do concentrate labeled octreotide but not radioiodine, the use of somatostatin analogues labeled with In-111 or [Y-90] can provide new therapeutic options. (J. Endocrinol. Invest. 24: 415-422, 2001) (C) 2001, Editrice Kurtis.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 18:55:23